Pharming’s Leniolisib On Track To Become First Disease-Modifying APDS Drug
Following NDA Acceptance
Executive Summary
The Dutch firm’s US filing for its first-in-class PI3K inhibitor has been accepted under priority review, bringing the asset closer to becoming the first disease-modifying option for a rare, genetic disorder.
You may also be interested in...
Pharming Leniolisib Launch Will Require Identifying Patients With Ultra Rare APDS
The company sees leniolisib as a way to expand its US and global commercial footprint before bringing in additional rare disease assets.
Keeping Track: Orphans Headline FDA Approvals; Gene Therapies Stand Out Among Submissions
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Accelerated Assessment Dry Spell Over As EMA Says Yes To Pharming’s Leniolisib
Leniolisib has become the first product to be granted accelerated assessment status by the European Medicines Agency this year.